Clinical Trial Update: Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of amcenestrant (SAR439859) as a single agent and in combination for postmenopausal women with estrogen receptor-positive advanced breast canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Amcenestrant (SAR439859)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-11-24